Labcorp Unveils 2029 Targets: 5-8% Revenue CAGR, 8.5-11.5% EPS Growth
LH sits 26% above its 52-week low of $244.52.
Summary
At its Investor Day, Labcorp laid out long-term financial targets through 2029: 5-8% annual revenue growth, 8.5-11.5% adjusted EPS growth, 75-150 bps of operating margin expansion, and free cash flow growth matching EPS. The company also reaffirmed 2026 guidance of $18.10-$18.55 EPS and $14.71B-$14.83B revenue, both above consensus. Four strategic priorities were highlighted: specialty testing, health system and pharma partnerships, personalized health, and AI/robotics integration. Shares fell 3.73% to $309.12 on the day, suggesting the market may have wanted more aggressive targets or was reacting to the reaffirmation rather than new upside. The long-term EPS growth range implies meaningful margin leverage and capital deployment, but the stock's decline indicates investors are not yet convinced.
At the time of this announcement, LH was trading at $307.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $25B. The 52-week trading range was $244.52 to $341.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Benzinga.